RSV Vaccine Campaign Ending: Dates & Territories
- Respiratory syncytial virus (RSV) vaccination and immunization campaigns are drawing to a close across much of France, coinciding with a significant decrease in viral circulation observed in recent...
- The primary goal was to reduce severe RSV infections through the availability of preventative treatments, including Abrysvo, Beyfortus, and Synagis (for hospital use).
- Campaign end dates were determined based on local epidemiological specifics.
Respiratory syncytial virus (RSV) vaccination and immunization campaigns are drawing to a close across much of France, coinciding with a significant decrease in viral circulation observed in recent weeks. Initiated in September , the campaign aimed to protect vulnerable populations, particularly newborns and infants, as the winter season approached.
The primary goal was to reduce severe RSV infections through the availability of preventative treatments, including Abrysvo, Beyfortus, and Synagis (for hospital use). Targeted groups included pregnant women, newborns, and infants – populations particularly susceptible to respiratory complications associated with the virus.
Campaign End Dates Vary by Territory
Campaign end dates were determined based on local epidemiological specifics. The campaign will conclude on , in metropolitan France, Saint Barthélemy, and Saint Martin. It will end on , in Guadeloupe and Martinique, and on , in Mayotte.
However, to address individual clinical situations or specific local epidemiological contexts, healthcare professionals may continue immunization on a case-by-case basis until , in metropolitan France, Saint Barthélemy, and Saint Martin, following standard billing procedures.
Continued Campaign in French Guiana
In French Guiana, the vaccination and immunization campaign continues without a defined end date. Due to year-round RSV circulation, continuous availability of preventative treatments is recommended.
Regarding Réunion, further details will be communicated later concerning the continuation of the campaign, depending on the evolution of the local health situation.
Decision Based on Epidemiological Analysis
The Directorate-General of Health consulted with Santé publique France to determine campaign end dates. This decision is based on an analysis of the epidemiological trends observed in metropolitan France and across all overseas departments and regions, confirming a decrease in viral circulation in most territories.
RSV is a common respiratory virus that typically causes mild, cold-like symptoms. However, it can be particularly serious for infants and older adults, and is the most common cause of hospitalization in U.S. Infants. Symptoms can include runny nose, decreased appetite, coughing, sneezing, and fever. In very young infants, symptoms may also include irritability, decreased activity, or pauses in breathing.
Preventative measures, such as nirsevimab (Beyfortus), a long-acting RSV monoclonal antibody, have been key to this year’s campaign. Unlike vaccines, monoclonal antibodies do not activate the immune system; instead, they provide direct protection against the virus. The optimal timing for administering nirsevimab is shortly before the RSV season begins, or within a baby’s first week of life if born during the RSV season.
The Philadelphia Immunization Program has provided guidance regarding unused doses of nirsevimab. Unexpired doses should not be discarded and can be safely stored until their expiration date for use when the RSV season resumes on . If a dose expires before that date, a vaccine return should be processed after the expiration date.
In the United States, the CDC recommends seasonal administration of infant RSV antibodies from October through March in most areas. Both maternal RSV vaccination (Pfizer’s Abrysvo) and infant immunization with a monoclonal antibody are recommended to prevent severe RSV disease in infants, though most infants will not need both.
Healthcare providers are encouraged to discuss both options with parents and consider patient preferences when deciding which product is best for their family. It’s important to note that RSV vaccine recommendations for people ages 50 and older have been updated as of , and this information will be reflected in updated guidance soon.
The success of this year’s campaign, and the ongoing monitoring of RSV circulation, are crucial steps in protecting vulnerable populations from the potentially serious effects of this common respiratory virus. Continued vigilance and adherence to public health recommendations remain essential as we move forward.